{
    "id": "33d9b82a-4f7a-137c-e063-6294a90a38e4",
    "code": {
        "code": "34391-3",
        "codeSystem": "2.16.840.1.113883.6.1",
        "displayName": "HUMAN PRESCRIPTION DRUG LABEL"
    },
    "organization": "Janssen Biotech, Inc.",
    "effectiveTime": "20250428",
    "ingredients": [
        {
            "name": "HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE",
            "code": "X573657P6P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27570"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27570"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53422"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R",
            "chebi_id": null,
            "drugbank_id": "DB01638"
        },
        {
            "name": "GOLIMUMAB",
            "code": "91X1KLU43E",
            "chebi_id": null,
            "drugbank_id": "DB06674"
        }
    ],
    "indications": [
        {
            "text": "1 usage simponi aria tumor necrosis factor ( tnf ) blocker indicated treatment of: adult patients moderately severely active rheumatoid arthritis ( rheumatoid arthritis ) combination methotrexate ( 1.1 ) active psoriatic arthritis ( psa ) patients 2 years age older ( 1.2 ) adult patients active ankylosing spondylitis ( ) ( 1.3 ) active polyarticular juvenile idiopathic arthritis ( pjia ) patients 2 years age older ( 1.4 ) 1.1 rheumatoid arthritis ( rheumatoid arthritis ) simponi aria, combination methotrexate ( mtx ) , indicated treatment adult patients moderately severely active rheumatoid arthritis. 1.2 psoriatic arthritis ( psa ) simponi aria indicated treatment active psoriatic arthritis patients 2 years age older. 1.3 ankylosing spondylitis ( ) simponi aria indicated treatment adult patients active ankylosing spondylitis. 1.4 polyarticular juvenile idiopathic arthritis ( pjia ) simponi aria indicated treatment active polyarticular juvenile idiopathic arthritis ( pjia ) patients 2 years age older.",
            "doid_id": "http://purl.obolibrary.org/obo/DOID_848",
            "orphanet_id": null
        }
    ],
    "contraindications": [
        {
            "text": "4 none. none ( 4 )",
            "doid_id": null,
            "orphanet_id": null
        }
    ],
    "warningsAndPrecautions": "5 serious infections: start simponi aria active infection. infection develops, monitor carefully, stop simponi aria infection becomes serious ( 5.1 ) . invasive fungal infections: patients develop systemic illness simponi aria, consider empiric antifungal therapy reside travel regions mycoses endemic ( 5.1 ) . hepatitis b reactivation: monitor hbv carriers several months therapy. reactivation occurs, stop simponi aria begin anti-viral therapy ( 5.1 ) . malignancies: cases lymphoma observed among patients receiving tnf blockers compared patients control groups. cases malignancies observed among patients receiving tnf blockers ( 5.2 ) . congestive heart failure: worsening, new onset, may occur. stop simponi aria new worsening symptoms occur ( 5.3 ) . demyelinating disorders: exacerbation new onset may occur ( 5.4 ) . lupus-like syndrome: discontinue simponi aria symptoms develop ( 5.5 ) . hypersensitivity reactions: serious systemic hypersensitivity including anaphylaxis may occur ( 5.11 ) . 5.1 serious infections patients treated simponi aria increased risk developing serious infections involving various organ systems sites may lead hospitalization death. opportunistic infections due bacterial, mycobacterial, invasive fungal, viral, parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, tuberculosis reported tnf-blockers. patients frequently presented disseminated rather localized disease. concomitant tnf-blocker abatacept anakinra associated higher risk serious infections; therefore, concomitant simponi aria biologic products recommended [see . ( 5.6 , 5.7 ) ( 7.2 ) ] treatment simponi aria initiated patients active infection, including clinically important localized infections. patients greater 65 years age, patients co-morbid conditions and/or patients taking concomitant immunosuppressants corticosteroids methotrexate may greater risk infection. consider risks benefits treatment prior initiating simponi aria patients: chronic recurrent infection; exposed tuberculosis; history opportunistic infection; resided traveled areas endemic tuberculosis endemic mycoses, histoplasmosis, coccidioidomycosis, blastomycosis; underlying conditions may predispose infection. monitoring closely monitor patients development signs symptoms infection treatment simponi aria. discontinue simponi aria patient develops serious infection, opportunistic infection, sepsis. patients develop new infection treatment simponi aria, perform prompt complete diagnostic workup appropriate immunocompromised patient initiate appropriate antimicrobial therapy closely monitor them. tuberculosis cases reactivation tuberculosis new tuberculosis infections observed patients receiving tnf-blockers, including patients previously received treatment latent active tuberculosis. evaluate patients tuberculosis risk factors test latent infection prior initiating simponi aria periodically therapy. treatment latent tuberculosis infection prior therapy tnf-blockers shown reduce risk tuberculosis reactivation therapy. prior initiating simponi aria, assess treatment latent tuberculosis needed; induration 5 mm greater positive tuberculin skin test, even patients previously vaccinated bacille calmette-guerin ( bcg ) . consider anti-tuberculosis therapy prior initiation simponi aria patients past history latent active tuberculosis adequate course treatment cannot confirmed, patients negative test latent tuberculosis risk factors tuberculosis infection. consultation physician expertise treatment tuberculosis recommended aid decision whether initiating anti-tuberculosis therapy appropriate individual patient. cases active tuberculosis occurred patients treated subcutaneous formulation golimumab treatment latent tuberculosis. monitor patients development signs symptoms tuberculosis including patients tested negative latent tuberculosis infection prior initiating therapy, patients treatment latent tuberculosis, patients previously treated tuberculosis infection. consider tuberculosis differential diagnosis patients develop new infection simponi aria treatment, especially patients previously recently traveled countries high prevalence tuberculosis, close contact person active tuberculosis. invasive fungal infections patients develop serious systemic illness reside travel regions mycoses endemic, consider invasive fungal infection differential diagnosis. consider appropriate empiric antifungal therapy take account risk severe fungal infection risks antifungal therapy diagnostic workup performed. antigen antibody testing histoplasmosis may negative patients active infection. aid management patients, consider consultation physician expertise diagnosis treatment invasive fungal infections. hepatitis b virus reactivation tnf-blockers, simponi aria member, associated reactivation hepatitis b virus ( hbv ) patients chronic hepatitis b carriers ( i.e. , surface antigen positive ) . instances, hbv reactivation occurring conjunction tnf-blocker therapy fatal. majority reports occurred patients received concomitant immunosuppressants. patients tested hbv infection initiating tnf-blocker therapy. patients test positive hepatitis b surface antigen, consultation physician expertise treatment hepatitis b recommended initiating tnf-blocker therapy. risks benefits treatment considered prior prescribing tnf-blockers, including simponi aria, patients carriers hbv. adequate data available whether antiviral therapy reduce risk hbv reactivation hbv carriers treated tnf-blockers. patients carriers hbv require treatment tnf-blockers closely monitored laboratory signs active hbv infection throughout therapy several months following termination therapy. patients develop hbv reactivation, tnf-blockers stopped antiviral therapy appropriate supportive treatment initiated. safety resuming tnf-blockers hbv reactivation controlled known. therefore, prescribers exercise caution considering resumption tnf-blockers situation monitor patients closely. 5.2 malignancies malignancies pediatric patients malignancies, fatal, reported among children, adolescents, young adults received treatment tnf-blocking agents ( initiation therapy \u2264 18 years age ) , including golimumab. approximately half cases lymphomas, including hodgkin's non-hodgkin's lymphoma. cases represented variety malignancies, including rare malignancies usually associated immunosuppression, malignancies usually observed children adolescents. malignancies occurred median 30 months ( range 1 84 months ) first dose tnf-blocker therapy. patients receiving concomitant immunosuppressants. cases reported postmarketing derived variety sources, including registries spontaneous postmarketing reports. malignancies adult patients risks benefits tnf-blocker treatment including simponi aria considered prior initiating therapy patients known malignancy successfully treated non-melanoma skin cancer ( nmsc ) considering continuing tnf-blocker patients develop malignancy. controlled portions trials tnf-blockers including subcutaneous formulation golimumab cases lymphoma observed among patients receiving anti-tnf treatment compared patients control groups. patients rheumatoid arthritis chronic inflammatory diseases, particularly patients highly active disease and/or chronic exposure immunosuppressant therapies, may higher risk ( several fold ) general population development lymphoma, even absence tnf-blocking therapy. cases acute chronic leukemia reported tnf-blocker use, including simponi aria, rheumatoid arthritis indications. even absence tnf-blocker therapy, patients rheumatoid arthritis may higher risk ( approximately 2-fold ) general population development leukemia. rare postmarketing cases hepatosplenic t-cell lymphoma ( hstcl ) reported patients treated tnf-blocking agents. rare type t-cell lymphoma aggressive disease course usually fatal. nearly reported tnf-blocker associated cases occurred patients crohn's disease ulcerative colitis. majority adolescent young adult males. almost patients received treatment azathioprine ( aza ) 6-mercaptopurine ( 6\u2013mp ) concomitantly tnf-blocker prior diagnosis. risk development hepatosplenic t-cell lymphoma patients treated tnf-blockers cannot excluded. melanoma merkel cell carcinoma reported patients treated tnf-blocking agents, including simponi aria. periodic skin examination recommended patients, particularly risk factors skin cancer. controlled trials tnf-blockers patients higher risk malignancies ( e.g. , patients chronic obstructive pulmonary disease [chronic obstructive pulmonary disease] , patients wegener's granulomatosis treated concomitant cyclophosphamide ) greater portion malignancies occurred tnf-blocker group compared controlled group. exploratory trial evaluating subcutaneous formulation golimumab patients severe persistent asthma, patients treated golimumab reported malignancies compared control patients. significance finding unknown. controlled portion phase 3 trial rheumatoid arthritis simponi aria, incidence malignancies lymphoma nmsc per 100-patient-years follow-up 0.56 ( 95% ci: 0.01, 3.11 ) simponi aria group compared incidence 0 ( 95% ci: 0.00, 3.79 ) placebo group. 5.3 congestive heart failure cases worsening congestive heart failure ( congestive heart failure ) new onset congestive heart failure reported tnf-blockers, including simponi aria. cases fatal outcome. several exploratory trials tnf-blockers treatment congestive heart failure, greater proportions tnf-blocker treated patients congestive heart failure exacerbations requiring hospitalization increased mortality. simponi aria studied patients history congestive heart failure simponi aria used caution patients congestive heart failure. decision made administer simponi aria patients congestive heart failure, patients closely monitored therapy, simponi aria discontinued new worsening symptoms congestive heart failure appear. 5.4 demyelinating disorders tnf-blockers, including simponi aria, associated rare cases new onset exacerbation central nervous system ( cns ) demyelinating disorders, including multiple sclerosis ( multiple sclerosis ) , peripheral demyelinating disorders, including guillain-barr\u00e9 syndrome. cases central demyelination, multiple sclerosis, optic neuritis, peripheral demyelinating polyneuropathy rarely reported patients treated golimumab. prescribers exercise caution considering tnf-blockers, including simponi aria, patients central peripheral nervous system demyelinating disorders. discontinuation simponi aria considered disorders develop. 5.5 autoimmunity treatment tnf blockers, including simponi aria, may result formation antinuclear antibodies ( ana ) . rarely, treatment tnf blockers, may result development lupus-like syndrome [see . patient develops symptoms suggestive lupus-like syndrome following treatment simponi aria, treatment discontinued. ( 6.1 ) ] 5.6 abatacept controlled trials, concurrent another tnf-blocker abatacept associated greater proportion serious infections tnf-blocker alone; combination therapy, compared tnf-blocker alone, demonstrated improved benefit treatment rheumatoid arthritis. therefore, combination tnf-blockers, including simponi aria, abatacept recommended [see . ( 7.2 ) ] 5.7 anakinra concurrent anakinra ( interleukin-1 antagonist ) another tnf-blocker associated greater portion serious infections neutropenia additional benefits compared tnf-blocker alone. therefore, combination anakinra tnf-blockers, including simponi aria, recommended [see . ( 7.2 ) ] 5.8 switching biological disease modifying antirheumatic drugs ( dmards ) care taken switching one biologic product another biologic product since overlapping biological activity may increase risk infection. 5.9 hematologic cytopenias reports pancytopenia, leukopenia, neutropenia, agranulocytosis, aplastic anemia, thrombocytopenia patients receiving golimumab. caution exercised using tnf-blockers, including simponi aria, patients significant cytopenias. 5.10 vaccinations/therapeutic infectious agents live vaccines avoid live vaccines patients treated simponi aria. patients receiving anti-tnf therapy, limited data available response live vaccination, secondary transmission infection live vaccines. live vaccines could result infections, including disseminated infections. live vaccines infants exposed simponi aria utero recommended 6 months following mother's last simponi aria infusion pregnancy [see . ( 7.3 ) ( 8.1 ) ] whenever possible update immunizations prior initiation treatment simponi aria following current immunization guidelines patients receiving immunosuppressive agents. advise patients discuss physician seeking immunizations. therapeutic infectious agents uses therapeutic infectious agents live attenuated bacteria ( e.g. , bcg bladder instillation treatment cancer ) could result infections, including disseminated infections. recommended therapeutic infectious agents given concurrently simponi aria. 5.11 hypersensitivity postmarketing experience, serious systemic hypersensitivity ( including anaphylaxis ) reported following subcutaneous intravenous formulations golimumab including simponi aria. hypersensitivity including hives, pruritus, dyspnea, nausea, reported infusion generally within hour infusion. occurred first golimumab. anaphylactic serious allergic reaction occurs, simponi aria discontinued immediately appropriate therapy instituted.",
    "adverseReactions": "6 serious were: serious infections [see ( 5.1 ) ] malignancies [see ( 5.2 ) ] common ( incidence \u2265 3% ) are: upper respiratory tract infection, alanine aminotransferase increased, viral infection, aspartate aminotransferase increased, neutrophil count decreased, bronchitis, hypertension, rash ( 6.1 ) . report suspected reactions, contact janssen biotech, inc. 1-800-janssen ( 1-800-526-7736 ) fda 1-800-fda-1088 www.fda.gov/medwatch. 6.1 trials experience trials conducted widely varying conditions, reaction rates observed trials cannot directly compared rates trials another may reflect rates observed practice. safety data described based one, randomized, double-blind, controlled phase 3 trial patients rheumatoid arthritis receiving simponi aria intravenous infusion ( trial rheumatoid arthritis ) . protocol included provisions patients taking placebo receive treatment simponi aria week 16 week 24 either patient response ( based uncontrolled disease activity ) design, events cannot always unambiguously attributed given treatment. comparisons placebo simponi aria based first 24 weeks exposure. trial rheumatoid arthritis included 197 control-treated patients 463 simponi aria-treated patients ( includes control-treated patients switched simponi aria week 16 ) . proportion patients discontinued treatment due controlled phase trial rheumatoid arthritis week 24 3.5% simponi aria-treated patients 0.5% placebo-treated patients. upper respiratory tract infection common reaction reported trial week 24 occurring 6.5% simponi aria-treated patients compared 7.6% control-treated patients, respectively. infections serious infections observed simponi aria-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis ( tb ) , invasive fungal infections. cases tb included pulmonary extrapulmonary tb. majority tb cases occurred countries high incidence rate tb [see . ( 5.1 ) ] controlled phase trial rheumatoid arthritis week 24, infections observed 27% simponi aria-treated patients compared 24% control-treated patients, serious infections observed 0.9% simponi aria-treated patients 0.0% control-treated patients. week 24, incidence serious infections per 100 patient-years follow-up 2.2 ( 95% ci 0.61, 5.71 ) simponi aria group, 0 ( 0.00, 3.79 ) placebo group. controlled uncontrolled portions trial rheumatoid arthritis, 958 total patient-years follow-up median follow-up approximately 92 weeks, incidence per 100 patient-years serious infections 4.07 ( 95% ci: 2.90, 5.57 ) patients receiving simponi aria [see . controlled uncontrolled portions trial rheumatoid arthritis, simponi aria-treated patients, incidence active tb per 100 patient-years 0.31 ( 95% ci: 0.06; 0.92 ) incidence opportunistic infections per 100 patient-years 0.42 ( 95% ci: 0.11, 1.07 ) . ( 5.1 ) ] malignancies one case malignancy lymphoma nmsc simponi aria reported week 24 controlled phase trial rheumatoid arthritis. controlled uncontrolled portions approximately 92 weeks, incidence malignancies per 100 patient-years, lymphoma nmsc, simponi aria-treated patients 0.31 ( 95% ci: 0.06, 0.92 ) incidence nmsc 0.1 ( 95% ci: 0.00, 0.58 ) . liver enzyme elevations reports severe hepatic including acute liver failure patients receiving tnf-blockers. controlled phase trial rheumatoid arthritis, week 24, alt elevations \u2265 5 \u00d7 uln occurred 0.8% simponi aria-treated patients 0% control-treated patients alt elevations \u2265 3 \u00d7 uln occurred 2.3% simponi aria-treated patients 2.5% control-treated patients. controlled phase trial psa, week 24, alt elevations \u2265 5 \u00d7 uln occurred 1.7% simponi aria-treated patients <1% placebo-treated patients, alt elevations \u2265 3 \u00d7 uln < 5 \u00d7 uln occurred 2.9% simponi aria-treated patients <1% placebo-treated patients. since many patients phase 3 trials also taking medications cause liver enzyme elevations ( e.g. , nonsteroidal anti-inflammatory drugs [nsaids] , mtx, isoniazid prophylaxis ) , relationship simponi aria liver enzyme elevation clear. autoimmune disorders autoantibodies week 20 trial rheumatoid arthritis, 17% simponi aria-treated patients 13% control patients newly antinuclear antibody ( ana ) -positive. patients, one simponi aria-treated patient control-treated patients newly positive anti-dsdna antibodies [see . ( 5.5 ) ] controlled phase trial rheumatoid arthritis week 24, 1.1% simponi aria infusions associated infusion reaction compared 0.2% infusions control group. common infusion reaction simponi aria-treated patients rash. serious infusion reported. table 1 summarizes occurred rate least 1% simponi aria + mtx group higher incidence placebo + mtx group controlled period trial rheumatoid arthritis week 24. table 1: reported \u2265 1% simponi aria-treated patients higher incidence placebo-treated patients trial rheumatoid arthritis week 24 placebo + mtx simponi aria + mtx patients treated 197 463 reaction infections infestations upper respiratory tract infection ( upper respiratory tract infection, nasopharyngitis, pharyngitis, laryngitis, rhinitis ) 12% 13% viral infections ( influenza herpes ) 3% 4% bacterial infections 0% 1% bronchitis 1% 3% vascular disorders hypertension 2% 3% skin subcutaneous disorders rash 1% 3% general disorders site conditions pyrexia 1% 2% blood lymphatic disorders leukopenia 0% 1% less common trial appear table 1 occurred < 1% simponi aria-treated patients trial rheumatoid arthritis week 24 appear section included following events listed system organ class: infections infestations: superficial fungal infection, sinusitis, abscess, lower respiratory tract infection ( pneumonia ) , pyelonephritis investigations: alanine aminotransferase ( alt ) increased, aspartate aminotransferase ( ast ) increased, neutrophil count decreased nervous system disorders: dizziness, paresthesia gastrointestinal disorders: constipation psoriatic arthritis trial psa evaluated 480 patients [see . similar observed patients rheumatoid arthritis, exception psoriasis ( new onset worsening, palmar/plantar pustular ) , occurred <1% simponi aria-treated patients. incidence reported trial psa similar trial rheumatoid arthritis exceptions higher incidence simponi aria alt increased ( 7.9% vs. 2.1% placebo ) , ast increased ( 5.4% vs. 2.1% placebo ) , neutrophil count decreased ( 4.6% vs. 2.1% placebo ) . ( 14.2 ) ] ankylosing spondylitis trial evaluated 208 patients [see . similar reported patients rheumatoid arthritis, exception higher incidence alt increased, occurred 2.9% simponi aria-treated patients compared none placebo-treated patients. ( 14.3 ) ] pediatric patients polyarticular juvenile idiopathic arthritis psoriatic arthritis trial pjia evaluated 127 patients jia active polyarthritis [see observed consistent established safety profile simponi aria adult patients rheumatoid arthritis psa. ( 8.4 ) ( 14.4 ) ] . 6.2 immunogenicity therapeutic proteins, potential immunogenicity. detection antibody formation highly dependent sensitivity specificity assay. additionally, observed incidence antibody ( including neutralizing antibody ) positivity assay may influenced several factors including assay methodology, sample handling, timing sample collection, concomitant medications, underlying disease. reasons, comparison incidence antibodies golimumab trials described incidence antibodies trials products may misleading. using enzyme immunoassay ( eia ) method, antibodies golimumab detected 13 ( 3% ) golimumab-treated patients following iv simponi aria combination mtx week 24 trial rheumatoid arthritis, neutralizing antibodies. drug-tolerant enzyme immunoassay ( drug-tolerant eia ) method detecting antibodies golimumab developed validated. method approximately 16-fold sensitive original eia method less interference golimumab serum. approximately 6 months, incidence antibodies golimumab drug-tolerant eia method trials rheumatoid arthritis, psa, as, pjia 21% , 19% , 19% 31% , respectively. tested, approximately one-third one-half neutralizing. patients rheumatoid arthritis, psa, pjia developed antibodies golimumab generally lower trough steady-state serum concentrations golimumab [see pharmacology ( 12.3 ) ] . 6.3 postmarketing experience following identified post-approval golimumab. reported voluntarily population uncertain size, always possible reliably estimate frequency establish causal relationship golimumab exposure: general disorders site conditions: infusion-related [see ( 5.11 ) ] neoplasm benign malignant : melanoma, merkel cell carcinoma [see ( 5.2 ) ] immune system disorders : serious systemic hypersensitivity ( including anaphylactic reaction ) [see , sarcoidosis ( 5.11 ) ] respiratory, thoracic mediastinal disorders : interstitial lung disease skin subcutaneous tissue disorders : skin exfoliation, lichenoid reactions, bullous skin",
    "indications_original": "1 INDICATIONS AND USAGE SIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 ) Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 ) 1.1 Rheumatoid Arthritis (RA) SIMPONI ARIA, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis. 1.2 Psoriatic Arthritis (PsA) SIMPONI ARIA is indicated for the treatment of active psoriatic arthritis in patients 2 years of age and older. 1.3 Ankylosing Spondylitis (AS) SIMPONI ARIA is indicated for the treatment of adult patients with active ankylosing spondylitis. 1.4 Polyarticular Juvenile Idiopathic Arthritis (pJIA) SIMPONI ARIA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.",
    "contraindications_original": "4 CONTRAINDICATIONS None. None ( 4 )",
    "warningsAndPrecautions_original": "5 WARNINGS AND PRECAUTIONS Serious Infections: Do not start SIMPONI ARIA during an active infection. If an infection develops, monitor carefully, and stop SIMPONI ARIA if infection becomes serious ( 5.1 ). Invasive Fungal Infections: For patients who develop a systemic illness on SIMPONI ARIA, consider empiric antifungal therapy for those who reside in or travel to regions where mycoses are endemic ( 5.1 ). Hepatitis B Reactivation: Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop SIMPONI ARIA and begin anti-viral therapy ( 5.1 ). Malignancies: More cases of lymphoma have been observed among patients receiving TNF blockers compared with patients in the control groups. Cases of other malignancies have been observed among patients receiving TNF blockers ( 5.2 ). Congestive Heart Failure: Worsening, or new onset, may occur. Stop SIMPONI ARIA if new or worsening symptoms occur ( 5.3 ). Demyelinating Disorders: Exacerbation or new onset may occur ( 5.4 ). Lupus-like Syndrome: Discontinue SIMPONI ARIA if symptoms develop ( 5.5 ). Hypersensitivity Reactions: Serious systemic hypersensitivity reactions including anaphylaxis may occur ( 5.11 ). 5.1 Serious Infections Patients treated with SIMPONI ARIA are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers. Patients have frequently presented with disseminated rather than localized disease. The concomitant use of a TNF-blocker and abatacept or anakinra was associated with a higher risk of serious infections; therefore, the concomitant use of SIMPONI ARIA and these biologic products is not recommended [see . Warnings and Precautions (5.6 , 5.7) and Drug Interactions (7.2) ] Treatment with SIMPONI ARIA should not be initiated in patients with an active infection, including clinically important localized infections. Patients greater than 65 years of age, patients with co-morbid conditions and/or patients taking concomitant immunosuppressants such as corticosteroids or methotrexate may be at greater risk of infection. Consider the risks and benefits of treatment prior to initiating SIMPONI ARIA in patients: with chronic or recurrent infection; who have been exposed to tuberculosis; with a history of an opportunistic infection; who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis; or with underlying conditions that may predispose them to infection. Monitoring Closely monitor patients for the development of signs and symptoms of infection during and after treatment with SIMPONI ARIA. Discontinue SIMPONI ARIA if a patient develops a serious infection, an opportunistic infection, or sepsis. For patients who develop a new infection during treatment with SIMPONI ARIA, perform a prompt and complete diagnostic workup appropriate for an immunocompromised patient and initiate appropriate antimicrobial therapy and closely monitor them. Tuberculosis Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF-blockers, including patients who have previously received treatment for latent or active tuberculosis. Evaluate patients for tuberculosis risk factors and test for latent infection prior to initiating SIMPONI ARIA and periodically during therapy. Treatment of latent tuberculosis infection prior to therapy with TNF-blockers has been shown to reduce the risk of tuberculosis reactivation during therapy. Prior to initiating SIMPONI ARIA, assess if treatment for latent tuberculosis is needed; An induration of 5 mm or greater is a positive tuberculin skin test, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG). Consider anti-tuberculosis therapy prior to initiation of SIMPONI ARIA in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating anti-tuberculosis therapy is appropriate for an individual patient. Cases of active tuberculosis have occurred in patients treated with the subcutaneous formulation of golimumab during and after treatment for latent tuberculosis. Monitor patients for the development of signs and symptoms of tuberculosis including patients who tested negative for latent tuberculosis infection prior to initiating therapy, patients who are on treatment for latent tuberculosis, or patients who were previously treated for tuberculosis infection. Consider tuberculosis in the differential diagnosis in patients who develop a new infection during SIMPONI ARIA treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis. Invasive Fungal Infections If patients develop a serious systemic illness and they reside or travel in regions where mycoses are endemic, consider invasive fungal infection in the differential diagnosis. Consider appropriate empiric antifungal therapy and take into account both the risk for severe fungal infection and the risks of antifungal therapy while a diagnostic workup is being performed. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. To aid in the management of such patients, consider consultation with a physician with expertise in the diagnosis and treatment of invasive fungal infections. Hepatitis B Virus Reactivation The use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic hepatitis B carriers (i.e., surface antigen positive). In some instances, HBV reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The majority of these reports have occurred in patients who received concomitant immunosuppressants. All patients should be tested for HBV infection before initiating TNF-blocker therapy. For patients who test positive for hepatitis B surface antigen, consultation with a physician with expertise in the treatment of hepatitis B is recommended before initiating TNF-blocker therapy. The risks and benefits of treatment should be considered prior to prescribing TNF-blockers, including SIMPONI ARIA, to patients who are carriers of HBV. Adequate data are not available on whether antiviral therapy can reduce the risk of HBV reactivation in HBV carriers who are treated with TNF-blockers. Patients who are carriers of HBV and require treatment with TNF-blockers should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, TNF-blockers should be stopped and antiviral therapy with appropriate supportive treatment should be initiated. The safety of resuming TNF-blockers after HBV reactivation has been controlled is not known. Therefore, prescribers should exercise caution when considering resumption of TNF-blockers in this situation and monitor patients closely. 5.2 Malignancies Malignancies in Pediatric Patients Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy \u2264 18 years of age), including golimumab. Approximately half the cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression, and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months (range 1 to 84 months) after the first dose of TNF-blocker therapy. Most of the patients were receiving concomitant immunosuppressants. Most cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports. Malignancies in Adult Patients The risks and benefits of TNF-blocker treatment including SIMPONI ARIA should be considered prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing a TNF-blocker in patients who develop a malignancy. In the controlled portions of clinical trials of TNF-blockers including the subcutaneous formulation of golimumab more cases of lymphoma have been observed among patients receiving anti-TNF treatment compared with patients in the control groups. Patients with RA and other chronic inflammatory diseases, particularly patients with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at higher risk (up to several fold) than the general population for the development of lymphoma, even in the absence of TNF-blocking therapy. Cases of acute and chronic leukemia have been reported with TNF-blocker use, including SIMPONI ARIA, in rheumatoid arthritis and other indications. Even in the absence of TNF-blocker therapy, patients with rheumatoid arthritis may be at a higher risk (approximately 2-fold) than the general population for the development of leukemia. Rare postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF-blocking agents. This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal. Nearly all of the reported TNF-blocker associated cases have occurred in patients with Crohn's disease or ulcerative colitis. The majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine (AZA) or 6-mercaptopurine (6\u2013MP) concomitantly with a TNF-blocker at or prior to diagnosis. A risk for the development for hepatosplenic T-cell lymphoma in patients treated with TNF-blockers cannot be excluded. Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF-blocking agents, including SIMPONI ARIA. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. In controlled trials of other TNF-blockers in patients at higher risk for malignancies (e.g., patients with chronic obstructive pulmonary disease [COPD], patients with Wegener's granulomatosis treated with concomitant cyclophosphamide) a greater portion of malignancies occurred in the TNF-blocker group compared to the controlled group. In an exploratory clinical trial evaluating the use of the subcutaneous formulation of golimumab in patients with severe persistent asthma, more patients treated with golimumab reported malignancies compared with control patients. The significance of this finding is unknown. During the controlled portion of the Phase 3 trial in RA for SIMPONI ARIA, the incidence of malignancies other than lymphoma and NMSC per 100-patient-years of follow-up was 0.56 (95% CI: 0.01, 3.11) in the SIMPONI ARIA group compared with an incidence of 0 (95% CI: 0.00, 3.79) in the placebo group. 5.3 Congestive Heart Failure Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF-blockers, including SIMPONI ARIA. Some cases had a fatal outcome. In several exploratory trials of other TNF-blockers in the treatment of CHF, there were greater proportions of TNF-blocker treated patients who had CHF exacerbations requiring hospitalization or increased mortality. SIMPONI ARIA has not been studied in patients with a history of CHF and SIMPONI ARIA should be used with caution in patients with CHF. If a decision is made to administer SIMPONI ARIA to patients with CHF, these patients should be closely monitored during therapy, and SIMPONI ARIA should be discontinued if new or worsening symptoms of CHF appear. 5.4 Demyelinating Disorders Use of TNF-blockers, including SIMPONI ARIA, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS), and peripheral demyelinating disorders, including Guillain-Barr\u00e9 syndrome. Cases of central demyelination, MS, optic neuritis, and peripheral demyelinating polyneuropathy have rarely been reported in patients treated with golimumab. Prescribers should exercise caution in considering the use of TNF-blockers, including SIMPONI ARIA, in patients with central or peripheral nervous system demyelinating disorders. Discontinuation of SIMPONI ARIA should be considered if these disorders develop. 5.5 Autoimmunity Treatment with TNF blockers, including SIMPONI ARIA, may result in the formation of antinuclear antibodies (ANA). Rarely, treatment with TNF blockers, may result in the development of a lupus-like syndrome [see . If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with SIMPONI ARIA, treatment should be discontinued. Adverse Reactions (6.1) ] 5.6 Use with Abatacept In controlled trials, the concurrent administration of another TNF-blocker and abatacept was associated with a greater proportion of serious infections than the use of a TNF-blocker alone; and the combination therapy, compared to the use of a TNF-blocker alone, has not demonstrated improved clinical benefit in the treatment of RA. Therefore, the combination of TNF-blockers, including SIMPONI ARIA, and abatacept is not recommended [see . Drug Interactions (7.2) ] 5.7 Use with Anakinra Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocker was associated with a greater portion of serious infections and neutropenia and no additional benefits compared with the TNF-blocker alone. Therefore, the combination of anakinra with TNF-blockers, including SIMPONI ARIA, is not recommended [see . Drug Interactions (7.2) ] 5.8 Switching Between Biological Disease Modifying Antirheumatic Drugs (DMARDs) Care should be taken when switching from one biologic product to another biologic product since overlapping biological activity may further increase the risk of infection. 5.9 Hematologic Cytopenias There have been reports of pancytopenia, leukopenia, neutropenia, agranulocytosis, aplastic anemia, and thrombocytopenia in patients receiving golimumab. Caution should be exercised when using TNF-blockers, including SIMPONI ARIA, in patients who have or have had significant cytopenias. 5.10 Vaccinations/Therapeutic Infectious Agents Live Vaccines Avoid live vaccines in patients treated with SIMPONI ARIA. In patients receiving anti-TNF therapy, limited data are available on the response to live vaccination, or on the secondary transmission of infection by live vaccines. Use of live vaccines could result in clinical infections, including disseminated infections. Administration of live vaccines to infants exposed to SIMPONI ARIA in utero is not recommended for 6 months following the mother's last SIMPONI ARIA infusion during pregnancy [see . Drug Interactions (7.3) and Use in Specific Populations (8.1) ] Whenever possible update immunizations prior to initiation of treatment with SIMPONI ARIA following current immunization guidelines for patients receiving immunosuppressive agents. Advise patients to discuss with the physician before seeking any immunizations. Therapeutic Infectious Agents Other uses of therapeutic infectious agents such as live attenuated bacteria (e.g., BCG bladder instillation for the treatment of cancer) could result in clinical infections, including disseminated infections. It is recommended that therapeutic infectious agents not be given concurrently with SIMPONI ARIA. 5.11 Hypersensitivity Reactions In postmarketing experience, serious systemic hypersensitivity reactions (including anaphylaxis) have been reported following administration of the subcutaneous and intravenous formulations of golimumab including SIMPONI ARIA. Hypersensitivity reactions including hives, pruritus, dyspnea, and nausea, were reported during infusion and generally within an hour after infusion. Some of these reactions occurred after the first administration of golimumab. If an anaphylactic or other serious allergic reaction occurs, administration of SIMPONI ARIA should be discontinued immediately and appropriate therapy instituted.",
    "adverseReactions_original": "6 ADVERSE REACTIONS The most serious adverse reactions were: Serious Infections [see Warnings and Precautions (5.1) ] Malignancies [see Warnings and Precautions (5.2) ] Most common adverse reactions (incidence \u2265 3%) are: upper respiratory tract infection, alanine aminotransferase increased, viral infection, aspartate aminotransferase increased, neutrophil count decreased, bronchitis, hypertension, and rash ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Janssen Biotech, Inc. at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety data described below are based on one, randomized, double-blind, controlled Phase 3 trial in patients with RA receiving SIMPONI ARIA by intravenous infusion (Trial RA). The protocol included provisions for patients taking placebo to receive treatment with SIMPONI ARIA at Week 16 or Week 24 either by patient response (based on uncontrolled disease activity) or by design, so that adverse events cannot always be unambiguously attributed to a given treatment. Comparisons between placebo and SIMPONI ARIA were based on the first 24 weeks of exposure. Trial RA included 197 control-treated patients and 463 SIMPONI ARIA-treated patients (which includes control-treated patients who switched to SIMPONI ARIA at Week 16). The proportion of patients who discontinued treatment due to adverse reactions in the controlled phase of Trial RA through Week 24 was 3.5% for SIMPONI ARIA-treated patients and 0.5% for placebo-treated patients. Upper respiratory tract infection was the most common adverse reaction reported in the trial through Week 24 occurring in 6.5% of SIMPONI ARIA-treated patients as compared with 7.6% of control-treated patients, respectively. Infections Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections. Cases of TB included pulmonary and extrapulmonary TB. The majority of the TB cases occurred in countries with a high incidence rate of TB [see . Warnings and Precautions (5.1) ] In the controlled phase of Trial RA through Week 24, infections were observed in 27% of SIMPONI ARIA-treated patients compared with 24% of control-treated patients, and serious infections were observed in 0.9% of SIMPONI ARIA-treated patients and 0.0% of control-treated patients. Through Week 24, the incidence of serious infections per 100 patient-years of follow-up was 2.2 (95% CI 0.61, 5.71) for the SIMPONI ARIA group, and 0 (0.00, 3.79) for the placebo group. In the controlled and uncontrolled portions of Trial RA, 958 total patient-years of follow-up with a median follow-up of approximately 92 weeks, the incidence per 100 patient-years of all serious infections was 4.07 (95% CI: 2.90, 5.57) in patients receiving SIMPONI ARIA [see . In the controlled and uncontrolled portions of Trial RA, in SIMPONI ARIA-treated patients, the incidence of active TB per 100 patient-years was 0.31 (95% CI: 0.06; 0.92) and the incidence of other opportunistic infections per 100 patient-years was 0.42 (95% CI: 0.11, 1.07). Warnings and Precautions (5.1) ] Malignancies One case of malignancy other than lymphoma and NMSC with SIMPONI ARIA was reported through Week 24 during the controlled phase of Trial RA. In the controlled and uncontrolled portions through approximately 92 weeks, the incidence of malignancies per 100 patient-years, other than lymphoma and NMSC, in SIMPONI ARIA-treated patients was 0.31 (95% CI: 0.06, 0.92) and the incidence of NMSC was 0.1 (95% CI: 0.00, 0.58). Liver Enzyme Elevations There have been reports of severe hepatic reactions including acute liver failure in patients receiving TNF-blockers. In the controlled phase of Trial RA, through Week 24, ALT elevations \u2265 5 \u00d7 ULN occurred in 0.8% of SIMPONI ARIA-treated patients and 0% of control-treated patients and ALT elevations \u2265 3 \u00d7 ULN occurred in 2.3% of SIMPONI ARIA-treated patients and 2.5% of control-treated patients. In the controlled phase of Trial PsA, through Week 24, ALT elevations \u2265 5 \u00d7 ULN occurred in 1.7% of SIMPONI ARIA-treated patients and <1% of placebo-treated patients, and ALT elevations \u2265 3 \u00d7 ULN to < 5 \u00d7 ULN occurred in 2.9% of SIMPONI ARIA-treated patients and <1% of placebo-treated patients. Since many of the patients in the Phase 3 trials were also taking medications that cause liver enzyme elevations (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs], MTX, or isoniazid prophylaxis), the relationship between SIMPONI ARIA and liver enzyme elevation is not clear. Autoimmune Disorders and Autoantibodies At Week 20 in Trial RA, 17% of SIMPONI ARIA-treated patients and 13% of control patients were newly antinuclear antibody (ANA)-positive. Of these patients, one SIMPONI ARIA-treated patient and no control-treated patients had newly positive anti-dsDNA antibodies [see . Warnings and Precautions (5.5) ] Administration Reactions In the controlled phase of Trial RA through Week 24, 1.1% of SIMPONI ARIA infusions were associated with an infusion reaction compared with 0.2% of infusions in the control group. The most common infusion reaction in SIMPONI ARIA-treated patients was rash. No serious infusion reactions were reported. Other Adverse Reactions Table 1 summarizes the adverse drug reactions that occurred at a rate of at least 1% in the SIMPONI ARIA + MTX group with a higher incidence than in the placebo + MTX group during the controlled period of Trial RA through Week 24. Table 1: Adverse Drug Reactions Reported by \u2265 1% of SIMPONI ARIA-Treated Patients and with a Higher Incidence than Placebo-Treated Patients in Trial RA through Week 24 Placebo + MTX SIMPONI ARIA + MTX Patients treated 197 463 Adverse Reaction Infections and infestations Upper respiratory tract infection (such as upper respiratory tract infection, nasopharyngitis, pharyngitis, laryngitis, and rhinitis) 12% 13% Viral infections (such as influenza and herpes) 3% 4% Bacterial infections 0% 1% Bronchitis 1% 3% Vascular disorders Hypertension 2% 3% Skin and subcutaneous disorders Rash 1% 3% General disorders and administration site conditions Pyrexia 1% 2% Blood and lymphatic disorders Leukopenia 0% 1% Other and Less Common Clinical Trial Adverse Drug Reactions Adverse drug reactions that do not appear in Table 1 or that occurred < 1% in SIMPONI ARIA-treated patients during Trial RA through Week 24 that do not appear in the Warnings and Precautions section included the following events listed by system organ class: Infections and infestations: Superficial fungal infection, sinusitis, abscess, lower respiratory tract infection (pneumonia), pyelonephritis Investigations: Alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased, neutrophil count decreased Nervous system disorders: Dizziness, paresthesia Gastrointestinal disorders: Constipation Psoriatic Arthritis Trial PsA evaluated 480 patients [see . The adverse reactions were similar to those observed in patients with RA, with the exception of psoriasis (new onset or worsening, palmar/plantar and pustular), which occurred in <1% of SIMPONI ARIA-treated patients. The incidence of the adverse reactions reported in Trial PsA were similar to Trial RA with the exceptions of higher incidence in SIMPONI ARIA for ALT increased (7.9% vs. 2.1% in placebo), AST increased (5.4% vs. 2.1% in placebo), and neutrophil count decreased (4.6% vs. 2.1% in placebo). Clinical Studies (14.2) ] Ankylosing Spondylitis Trial AS evaluated 208 patients [see . The adverse reactions were similar to those reported in patients with RA, with the exception of the higher incidence of ALT increased, which occurred in 2.9% of SIMPONI ARIA-treated patients compared with none of the placebo-treated patients. Clinical Studies (14.3) ] Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis Trial pJIA evaluated 127 patients with JIA with active polyarthritis [see The adverse reactions observed were consistent with the established safety profile of SIMPONI ARIA in adult patients with RA and PsA. Use in Specific Populations (8.4) and Clinical Studies (14.4) ]. 6.2 Immunogenicity As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to golimumab in the trials described below with the incidence of antibodies in other trials or to other products may be misleading. Using an enzyme immunoassay (EIA) method, antibodies to golimumab were detected in 13 (3%) golimumab-treated patients following IV administration of SIMPONI ARIA in combination with MTX through Week 24 of Trial RA, of which all were neutralizing antibodies. A drug-tolerant enzyme immunoassay (drug-tolerant EIA) method for detecting antibodies to golimumab was developed and validated. This method is approximately 16-fold more sensitive than the original EIA method with less interference from golimumab in serum. Through approximately 6 months, the incidence of antibodies to golimumab with the drug-tolerant EIA method for Trials RA, PsA, AS, and pJIA was 21%, 19%, 19% and 31%, respectively. Where tested, approximately one-third to one-half were neutralizing. Patients with RA, PsA, AS and pJIA who developed antibodies to golimumab generally had lower trough steady-state serum concentrations of golimumab [see Clinical Pharmacology (12.3) ]. 6.3 Postmarketing Experience The following adverse reactions have been identified during post-approval use of golimumab. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to golimumab exposure: General Disorders and Administration Site Conditions: Infusion-related reactions [see Warnings and Precautions (5.11) ] Neoplasm benign and malignant : Melanoma, Merkel cell carcinoma [see Warnings and Precautions (5.2) ] Immune system disorders : Serious systemic hypersensitivity reactions (including anaphylactic reaction) [see , sarcoidosis Warnings and Precautions (5.11) ] Respiratory, thoracic and mediastinal disorders : Interstitial lung disease Skin and subcutaneous tissue disorders : Skin exfoliation, lichenoid reactions, bullous skin reactions",
    "drug": [
        {
            "name": "HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27570"
        }
    ]
}